Clinical Trials Sponsored by Kira Pharmacenticals (US), LLC.

Total 21 results

Kira Pharmacenticals (US), LLC.

Not yet recruiting

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Kira Pharmacenticals (US), LLC.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Paroxysmal Nocturnal Hemoglobinuria

Australia
Kira Pharmacenticals (US), LLC.

Not yet recruiting

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Glomerulonephritis
Kira Pharmacenticals (US), LLC.

Not yet recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

Paroxysmal Nocturnal Hemoglobinuria

China
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Osmotica Pharmaceutical US LLC

Completed

Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

Parkinson's Disease

Argentina
Novartis Pharmaceuticals
XOMA (US) LLC

Completed

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States, Belgium, Canada, Italy, France, Hong Kong, Australia, United Kingdom, Singapore, Korea, Republic of, Germany
Novartis Pharmaceuticals
XOMA (US) LLC

Terminated

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Chronic Lymphocytic Leukemia

United States
US Oncology Research
Novartis Pharmaceuticals; Delta Clinical Research, LLC

Unknown

Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
MDD US Operations, LLC a subsidiary of Supernus...

Active, not recruiting

Infusion of Apomorphine: Long-term Safety Study (INFUS-ON)

Idiopathic Parkinson's Disease

United States
MDD US Operations, LLC a subsidiary of Supernus...

Completed

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) (AM IMPAKT)

Parkinson's Disease | Akinesia | Motor Symptoms | Hypomobility | Delayed Levodopa Onset

United States
MDD US Operations, LLC a subsidiary of Supernus...

Terminated

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN® (PERFORM)

Parkinson's Disease | Motor Symptoms

United States
Bausch Health Americas, Inc.
Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC

Terminated

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Crohn's Disease

United States
Bausch Health Americas, Inc.
Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC

Terminated

One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

Crohn's Disease

United States
Aphaia Pharma US LLC
NovaClin Medical Research Center S.R.L; ACC GmbH Analytical Clinical Concepts; SC Bioclinica... and other collaborators

Completed

Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects

Obese

Romania
Aphaia Pharma US LLC
BioClinica, Inc.; ACC GmbH Analytical Clinical Concepts, Germany; Nova-Clin Medical... and other collaborators

Completed

Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects

Obesity | Metabolic Syndrome

Romania
US Department of Veterans Affairs
Bristol-Myers Squibb; Sanofi; GE Healthcare; Merck Sharp & Dohme LLC; Pfizer; Astra... and other collaborators

Completed

Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

Myocardial Ischemia

United States, Canada

Clinical Trials Sponsored by Kira Pharmacenticals (US), LLC.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations